2018 Press Releases

Keyword Search
2018 | 2017 | 2016 | 2015 | 2014
01/08/18REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the Development and Commercialization of Treatments for Spinal Muscular Atrophy
AveXis acquires exclusive rights to entire NAV Technology Platform for the development of treatments for SMA Amended agreement permits assignment by AveXis upon a change of control without REGENXBIO’s consent REGENXBIO could receive up to $260 million, including $140 million in guaranteed upfront and annual payments              ROCKVILLE, Md. and CHICAGO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX) and AveXis, Inc. (Nasdaq:AVXS) today announced that they have enter... 
Printer Friendly Version
01/04/18REGENXBIO Provides Year-End 2017 Corporate Update
- Initiated third cohort dosing of RGX-314 Phase I clinical trial for wet AMD - - Initiated second cohort dosing of RGX-501 Phase I/II clinical trial for HoFH - - Anticipate completing dosing and presenting topline data from RGX-314 and RGX-501 trials in late 2018 - - Anticipate initiating dosing in clinical trials for MPS I and MPS II in first half 2018 - - Ended 2017 with greater than $175 million in cash, cash equivalents and marketable securities - ROCKVILLE, Md., Jan. 04, 2018 (GLOB... 
Printer Friendly Version